SCHEMBL4285950

SCHEMBL4285950

OC(c1[c]cccc1C(F)(F)F)N1CCNCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.43
SLC6A2 P23975 2/20 0.43
EPHX2 P34913 1/20 0.40
NCF1 P14598 1/20 0.35
OPRD1 P41143 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR2C P28335 8/20 0.34
CYP1A2 P05177 3/20 0.34
CYP2C19 P33261 1/20 0.34
CYP2C9 P11712 1/20 0.34
TACR1 P25103 1/20 0.34
HTR2B P41595 4/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ADRB2 P07550 1/20 0.33
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
HTR1D P28221 1/20 0.33
HTR3A P46098 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4285944 0.78 SLC6A4 (0.35) SLC6A4SLC6A2EPHX2OPRD1MEN1
SCHEMBL4764069 0.70 MEN1 (0.43) SLC6A4SLC6A2OPRD1MEN1KMT2A
SCHEMBL1065986 0.68 ALDH1A1 (0.31) ALDH1A1
SCHEMBL9260037 0.67 P2RX7 (0.37) ALDH1A1
SCHEMBL17238700 0.67 P2RX7 (0.33) ALDH1A1
SCHEMBL14938826 0.65 ADRB1 (0.41) SLC6A4SLC6A2OPRD1MEN1KMT2A
SCHEMBL4764075 0.64 MEN1 (0.43) SLC6A4SLC6A2OPRD1MEN1KMT2A
SCHEMBL10385675 0.63 MEN1 (0.66) SLC6A4SLC6A2OPRD1MEN1KMT2A
SCHEMBL27774299 0.63 ADRB1 (0.46) EPHX2NCF1HTR2CCYP1A2CYP2C19
SCHEMBL231778 0.61 EPHX2 (0.61) EPHX2NCF1CYP1A2CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137580-A1 Fused Heterocyclic Derivatives and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137580-A1 Fused Heterocyclic Derivatives and Use Thereof TIE1, KDR, FLT1 SLC6A4 2132/4885SLC6A2 2128/4885EPHX2 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.